CLPP

KEEP AMERICA BEAUTIFUL TO AWARD UP TO $375K IN GRANTS TO COMBAT CIGARETTE LITTER ACROSS THE COUNTRY

Retrieved on: 
Friday, February 2, 2024
Keep America Beautiful, Research, Recycling, Collection, Reynolds American, CLPP, Smoker, Organization, Tobacco

According to the Keep America Beautiful 2020 National Litter Study , cigarette butts are the nation’s single most littered item in the United States and comprise 20% of the litter found on the ground and in waterways.

Key Points: 
  • According to the Keep America Beautiful 2020 National Litter Study , cigarette butts are the nation’s single most littered item in the United States and comprise 20% of the litter found on the ground and in waterways.
  • Additionally, this research shows that smokers are significantly less likely to litter when convenient ash receptacles are available nearby.
  • “The number of cigarette butts found on our streets and within our waterways is alarming,” said Jennifer Lawson, President and CEO of Keep America Beautiful.
  • Information about CLPP grants and other Keep America Beautiful community grants are available here.

Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research

Retrieved on: 
Tuesday, January 18, 2022
Glioma, Research, RECIST, Patient, CLPP, Forward-looking statement, Private Securities Litigation Reform Act, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Desmoplastic small-round-cell tumor, Clinical Cancer Research, MBA, Safety, NASDAQ, Peter Anderson, GLOBE, Society, SD, ONC201, Paraganglioma, Acute myeloid leukemia, Smallpox, Wilms' tumor, American Society of Clinical Oncology, U.S. Securities and Exchange Commission, Cleveland Clinic, Company, DSRCT, DRD2, ASCO, Food, Neoplasm, Case Comprehensive Cancer Center, Sodium, Neuroblastoma, Trial of the century, KPS, Acquisition, Pharmaceutical industry, Medical imaging, Performance status, MD

ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist.

Key Points: 
  • ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist.
  • We look forward to continuing to explore additional tumors where ONC201 may provide therapeutic benefit to existing standards of care.
  • This open-label Phase 2 investigator-initiated study treated 30 patients with rare neuroendocrine tumors.
  • A third cohort included patients with other neuroendocrine tumors, including desmoplastic small round cell tumor (DSRCT), dosed weekly with ONC201.

Chimerix Announces Positive ONC201 Data in Recurrent H3 K27M-mutant Diffuse Midline Glioma to Be Presented at the Society for Neuro-Oncology Annual Meeting

Retrieved on: 
Friday, November 19, 2021
World Health Organization, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ONC201, Company, MD, Doctor of Philosophy, PFS, Prognosis, Progression-free survival, Society, Mutation, GLOBE, Glioma, World, Food, Private Securities Litigation Reform Act, CLPP, Sodium, Acute myeloid leukemia, ID, Investor, DRD2, Smallpox, HIV disease progression rates, Radiation, HGG, Brain, Fatigue, DCR, Pakistan Society of Neuro-Oncology, Trial of the century, Conference, CMC, Forward-looking statement, LGG, Glioblastoma, DOR, Survival, Life expectancy, Adult, Histology, NASDAQ, FDA, DMG, Quality of life, Patient, Plenary session, Safety, Acquisition, SNO, U.S. Securities and Exchange Commission, ORR, Disease, Chemistry, Pharmaceutical industry, Medical device, Medical imaging, Mobile phone

DURHAM, N.C., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the presentation of positive data from its 50-patient efficacy analysis of ONC201 for the treatment of recurrent H3 K27M-mutant diffuse midline glioma. ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist for the treatment of recurrent gliomas that harbor the H3 K27M- mutation.

Key Points: 
  • "The ONC201 data to be presented at SNO show impressive and consistent results in a disease where life expectancy is exceedingly limited.
  • There currently are no effective therapeutic options for patients with recurrent disease after radiation other than palliation.
  • ONC201 results are particularly notable in light of extended wash-out periods required to ensure isolation of ONC201 single agent effect.
  • It sets the stage for future study of ONC201 earlier in treatment," said Mike Sherman, Chief Executive Officer of Chimerix.

Chimerix Announces Positive Topline Results for ONC201 in Recurrent H3 K27M-mutant Glioma

Retrieved on: 
Thursday, November 4, 2021
Safety, MD, Chemistry, Mutation, Glioma, Radiation, Palliative care, Prognosis, Pakistan Society of Neuro-Oncology, Neoplasm, Patient, Private Securities Litigation Reform Act, NASDAQ, World Health Organization, FDA, World, Investor, Brain, Society, Food, SNO, ORR, ONC201, ID, Risk, MTTR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, CMC, Adult, Glioblastoma, Forward-looking statement, Company, Fatigue, CLPP, Trial of the century, Conference call, Acute myeloid leukemia, U.S. Securities and Exchange Commission, Acquisition, Hope, Confidence interval, GLOBE, Population, Doctor of Philosophy, HIV disease progression rates, DRD2, Smallpox, Sodium, Pharmaceutical industry, Medical imaging

DURHAM, N.C., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported positive topline data from its 50-patient efficacy analysis of ONC201 for the treatment of recurrent H3 K27M-mutant glioma. ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist for the treatment of recurrent gliomas that harbor the H3 K27M mutation.

Key Points: 
  • ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist for the treatment of recurrent gliomas that harbor the H3 K27M mutation.
  • The FDA granted ONC201 Fast Track Designation for the treatment of adult recurrent H3 K27M-mutant high-grade glioma, Rare Pediatric Disease Designation for treatment of H3 K27M-mutant glioma, and Orphan Drug Designations for the treatment of glioblastoma and for the treatment of malignant glioma.
  • Pediatric patients with recurrent glioma that carries the H3 K27M mutation have an even worse prognosis.
  • ONC201 is in development for recurrent H3 K27M mutant glioma.